Tanvi Patel, vice president and general manager of Amazon Pharmacy, and her co-panelists at the recent Bullseye event, explained why PBMs, payers and doctors are all hampering consumer choice when it comes to patients getting affordable drugs. The post Amazon Pharmacy Executive: Formularies are Anti-Choice appeared first on MedCity News.
Small group insurers are proposing a median 14% premium increase for 2027, driven by rising healthcare costs. The post Small Businesses Could Face Double-Digit Premium Hikes in 2027 appeared first on MedCity News.
Jazz Pharmaceuticals, maker of the blockbuster epilepsy drug Epidiolex, is acquiring Actio Biosciences and its lead drug in pivotal testing for a rare type of epilepsy with no FDA-approved treatments. It’s Jazz’s second epilepsy deal in the past year. The post Jazz Pharma Expands Again in Epilepsy With $850M Actio Bio Acquisition appeared first on…
In this episode of the MedCity Pivot Podcast, CVS Health Aetna’s chief digital and technology officer talks about how the insurance business is using AI, especially agentic AI, in healthcare. Point to note: AI is not used in automatic denials of coverage. The post MedCity Pivot: How Aetna is Adopting Agentic AI appeared first on…
Drug development isn’t limited by the amount of data we collect, but by our ability to preserve the context, meaning and relationships that transform data into evidence. The post AI in Drug Development is Not a Data Problem — It’s An Evidence Problem appeared first on MedCity News.
Ascension is pushing AI beyond note-taking to tackle the billing, order entry and nursing handoff work still weighing on clinicians after a patient visit ends. The post How to Keep Clinicians Satisfied, the Ascension Way appeared first on MedCity News.
[Sponsored] With home health fraud growing more sophisticated through AI, post-pay audits are no longer enough. Payers must shift to proactive, tech-driven prevention to catch improper claims before paying them. The post Compliance Alone Won’t Fix the Home Health Fraud Problem appeared first on MedCity News.
In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s total haul to nearly $440 million. Braveheart’s lead drug could be competitive with a blockbuster Bristol Myers Squibb medicine for a type of cardiomyopathy. The post Braveheart Bio’s $382M IPO…
In this episode, we’re joined by Cheryl Larson, president and CEO of the Midwest Business Group on Health, for our first in-person recording at MedCity News’ recent Bullseye event. The post MedCity FemFwd: Employer Strategies for Women’s Health appeared first on MedCity News.
Hinge Health’s acquisition of Cylinder expands it into GI care, but experts differ on whether employers will favor convenience or specialized solutions. The post Two Differing POVs Emerge About the Hinge-Cylinder Deal appeared first on MedCity News.